Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center
DOI: https://doi.org/10.2147/PPA.S390349
2023-03-23
Patient Preference and Adherence
Abstract:Anna Viola, 1 Maria Giulia Demarzo, 1, 2 Alfredo Abbruzzese, 1, 3 Marco Muscianisi, 1 Michele Francesco Chiappetta, 1, 3 Giuseppe Costantino, 1 Omar Ksissa, 1, 3 Angela Alibrandi, 4 Walter Fries 1 1 Department of Clinical and Experimental Medicine, IBD-Unit, University of Messina, Messina, Italy; 2 Department of Internal Medicine, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Gastroenterology Unit, University of Genoa, Genoa, Italy; 3 Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy; 4 Department of Economics; Unit of Statistical and Mathematical Sciences, University of Messina, Messina, Italy Correspondence: Anna Viola, Clinical Unit of Gastroenterology and Chronic Bowel Disorders, Department of Clinical and Experimental Medicine, Via Consolare Valeria 1, Messina, 9815, Italy, Tel +39 3338377928, Email Purpose: New therapeutic approaches for ulcerative colitis (UC) are now available, but there is still no robust evidence for predictors of poor outcomes. We aimed to evaluate the factors associated with a chronic active UC disease course. Patients and Methods: Data of all UC outpatients followed for at least 3 years after diagnosis between 2005 and 2018 were retrospectively collected. The primary aim was to identify risk factors for chronic active disease 3 years after diagnosis. Moreover, the following variables were investigated: proximal disease extension or disease regression, proctocolectomy, early use of biologics (BIO) or immunomodulators (IMM), hospitalization, colorectal cancer, and adherence. We defined adherence as both, taking the prescribed therapy and constancy in scheduled follow-up visits. Results: A total of 345 UC patients followed for a median period of 82 months were included. Patients with extensive colitis at diagnosis had a higher rate of chronic active disease 3 years after diagnosis (p< 0.012) together with a higher rate of surgery (p< 0.001) at maximum follow-up. Patients with pancolitis showed significant disease regression over time (51%) without differences in treatment. The only factor associated with chronic active disease was non-adherence (p < 0.03; OR 0.49, 95% CI: 0.26– 0.95). Adherent patients developed chronic active disease (p< 0.025) less frequently but did receive more frequent IMM (p< 0.045) or BIO (p< 0.009) therapy. Conclusion: Patients diagnosed with pancolitis were more likely to have chronic active disease and to undergo colectomy. The only predictor for developing chronically active UC regardless of disease extension was the lack of adherence to therapy within the first 3 years after diagnosis, underlining the importance of tight control of UC patients and the need to timely identify potential risk factors for non-adherence. Keywords: outcome, adherence, surgery, hospitalization, disease course Ulcerative Colitis (UC) is a chronic, potentially progressive and disabling disease that may extend to the entire colon. The clinical course of UC including the risk for surgery is still difficult to predict being characterized by periods of remission and exacerbation which have variable duration. A discrete percentage of patients will develop chronic active disease leading to very poor quality of life (QoL) and a high rate of surgery. 1,2 In a recent paediatric study, 3 the clusters adopted by Henriksen et al 4 were investigated during the first 5 years after diagnosis showing that more than 30% of the patients will develop a chronic active or intermittent disease course despite appropriate treatment. A timely identification of patients with a more disabling disease course over time would be helpful in order to recognize who to treat with a more aggressive therapy aimed to prevent complications and irreversible tissue damage, while, in those with indolent disease, overtreatment may be avoided, and consequently, potential side effects. However, despite numerous studies having been conducted, we are not yet able to stratify the majority of patients according to the risk for developing a more aggressive disease over time. 5 Unfortunately, beyond the four items of the risk matrix model proposed by Monstad et al 6 with important negative predictors such as age <40 years at diagnosis, pancolitis, signs of systemic inflammation and the early need for systemic steroids, with a colectomy rate that reaches 40% at 10 years after diagnosis, in the case of the presence of all four predictors, little progress has b -Abstract Truncated-
medicine, general & internal